NTB-928 for Ovarian Cancer

This trial explores the safety and effectiveness of a new treatment called NTB-928 for women with ovarian cancer that has returned after treatment or stopped responding to standard therapies. Researchers aim to understand how NTB-928 affects the body and immune system and to identify any potential side effects. Women whose ovarian cancer is not responding to standard treatments and who have tried other options might be suitable for this trial. The study seeks to determine the right dose of NTB-928 that effectively fights cancer with minimal side effects. As a Phase 1 trial, this research focuses on understanding how NTB-928 works in people, offering participants the opportunity to be among the first to receive this new treatment.

Research has shown that NTB-928 has a good safety record in lab tests and early studies. It helps the immune system attack ovarian cancer cells while avoiding healthy ones, aiming to protect normal tissues. Since this study is in its early phase, the main focus is on safety and patient tolerance of the treatment.

Unlike the standard treatments for ovarian cancer, which often include chemotherapy and targeted therapies like PARP inhibitors, NTB-928 offers a unique approach. NTB-928 is designed to target a specific pathway involved in cancer cell survival, potentially providing a new mechanism of action that current treatments don't address. Researchers are excited about NTB-928 because it could offer an alternative for patients who have not responded well to existing therapies, potentially improving outcomes with fewer side effects.

Research has shown that NTB-928, the investigational treatment in this trial, offers promise for ovarian cancer. This special type of antibody aids the body's immune cells, known as T cells, in locating and destroying cancer cells. These cancer cells often exhibit high levels of a protein called FOLR1, found in over 75% of ovarian cancer cases. Early results indicate that NTB-928 can target and eliminate these cancer cells without damaging normal cells. This approach offers hope to those whose cancer has recurred or stopped responding to other treatments. Although human studies provide limited information, this method targets a common trait of many ovarian tumors, potentially leading to better outcomes.¹²³⁴⁵